Shanghai Pharmaceuticals (HKG:2607, SHA:601607) completed the analysis of the results of the Phase II clinical trial of LT3001, a drug used for the treatment of acute stroke and acute ischemic stroke, according to a Shanghai Stock Exchange filing on Saturday.
The trial found that the drug was generally safe and well tolerated and it showed preliminary efficacy among subjects within 90 days of treatment.
The rights of the drug were bought from Shuntian Pharmaceutical Biotech in 2019 and it was approved for clinical trials in 2020, the Chinese pharmaceutical company said.
The company's shares fell 2% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。